Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission

Michele Francesco Di Tolla, Michele Libutti, Guido D’Onofrio, Alessandra Riccio, Serena Cabaro, Michele Longo, Alessia Parascandolo, Giusy Ferraro, Elia Formisano, Vittoria D’Esposito, Pietro FormisanoFrontiers in Immunology 2025 · DOI

Abstract

Despite the lack of a control group and the high attrition rate may represent limitations for this observational pilot study, we have provided evidence that nutritional intervention could be a promising complementary strategy in oncological management by modulating key inflammatory and metabolic pathways involved in tumor pathophysiology and comorbidities.

Introduction

For many cancer survivors, achieving remission is not the end of the clinical journey. Survivors often enter a state of Low-Grade Chronic Inflammation (LGCI), frequently termed "metabolic inflammation." This persistent inflammatory milieu is a significant driver of cardiometabolic comorbidities and may potentially elevate the risk of cancer recurrence. While the Mediterranean Diet (MD) is widely recognized as a gold standard for cardiovascular health, its specific molecular impact on the post-treatment oncological landscape has remained under-explored. This study aimed to bridge this gap by evaluating how a 6-month qualitative dietary intervention based on MD principles modulates inflammatory biomarkers, metabolic status, and body composition in patients recovering from breast, colorectal, and prostate cancers.

Methodology

This 6-month observational pilot study followed 132 patients in clinical remission (64 breast cancer, 52 colorectal cancer, and 16 prostate cancer). The intervention focused on a qualitative shift toward the Mediterranean model, emphasizing a low glycemic/insulinemic index, high fiber intake, healthy fats (primarily extra-virgin olive oil), and a reduction in processed meats.

To capture the multifaceted impact of the diet, the researchers employed an integrative phenotyping approach:

  • Bioimpedance Analysis: Multifrequency segmental body composition analyzers were used to track visceral adipose tissue (VAT), fat-free mass, and phase angles beyond standard BMI metrics.
  • Multiplex Biomarker Screening: Bio-Plex® assays quantified a 27-molecule panel of cytokines, chemokines, and growth factors, alongside a 10-molecule panel of metabolic markers including insulin, leptin, and ghrelin.
  • High-Dimensional Data Analysis: To synthesize these diverse data streams, the team utilized Multiple Factor Analysis (MFA) and non-linear dimensionality reduction techniques like t-SNE and UMAP. These methods allowed for the identification of complex associations between dietary habits, clinical variables, and molecular signatures.
Multiple Factor Analysis (MFA) of clinical, metabolic, and inflammatory variables across the study cohort.

Results and Discussion

High-Dimensional Analysis of Dietary Impact

The application of Multiple Factor Analysis (MFA) revealed a clear structure in the data, where inflammatory markers clustered tightly with visceral adipose tissue (VAT) and BMI at baseline. This reinforces the physiological link between adipose tissue distribution and systemic metabolic inflammation. As shown in the MFA plots, different variable groups (Anagraphic, Clinical, Dietary, Bioimpedantial, Cytokines, and Metabolic Markers) contribute uniquely to the variance observed in the patient population.

Tumor-Specific Molecular Signatures

A key finding of the study was the divergence in molecular response based on the primary tumor type. In breast cancer (BC) patients, the dietary benefits were predominantly metabolic, characterized by significant reductions in Leptin and Insulin. Conversely, in colorectal cancer (CC) patients, the intervention acted as a potent anti-inflammatory agent, significantly reducing pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Notably, these cytokine reductions in the CC group occurred even in the absence of significant weight loss, suggesting that the quality of nutrients (e.g., polyphenols and omega-3 fatty acids) directly modulates the immune environment.

Across the entire cohort, C-Reactive Protein (CRP) emerged as a universal barometer of success, showing significant reduction regardless of cancer subtype. Furthermore, the cohort experienced broad improvements in body composition, including significant decreases in weight, BMI, and VAT (all p < 0.001). Metabolic profiles improved globally, with significant increases in the anti-inflammatory hormone Adiponectin (p = 0.012) and decreases in Visfatin (p = 0.013).

Conclusion

This study provides evidence that a personalized Mediterranean diet can effectively modulate the inflammatory and metabolic pathways that persist after cancer treatment. By identifying tumor-specific responses, the research highlights the potential for "precision nutrition" in oncological follow-up. While limited by the lack of a control group and a high attrition rate (47%), the robust effect sizes observed, particularly in cytokine reduction for colorectal patients, warrant further investigation through large-scale randomized controlled trials. Future research should also explore the role of the gut-immune axis in mediating these systemic anti-inflammatory effects.

Summary updated

Abstract

Despite the lack of a control group and the high attrition rate may represent limitations for this observational pilot study, we have provided evidence that nutritional intervention could be a promising complementary strategy in oncological management by modulating key inflammatory and metabolic pathways involved in tumor pathophysiology and comorbidities.
BibTeX
@inproceedings{tolla2025unraveling,
  author = {Michele Francesco Di Tolla and Michele Libutti and Guido D’Onofrio and Alessandra Riccio and Serena Cabaro and Michele Longo and Alessia Parascandolo and Giusy Ferraro and Elia Formisano and Vittoria D’Esposito and Pietro Formisano},
  title = {{Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1666611},
}
Figure